Action Pharma secures funds for critical Phase II trial as it seeks development partner
This article was originally published in Scrip
Executive Summary
Action Pharma of Denmark has secured a convertible loan of €5 million from its four investors, in addition to the €2 million loan secured at the start of the year, which will be used to finance ongoing clinical studies of its lead drug candidate AP214. AP214 is a modified DMSH-peptide analogue in Phase IIa studies for the protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as its lead indication.